CELLDEX THERAPEUTICS, INC.
CLDX · NASDAQ
Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly effect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer.
Market Data
Price
$32.88
+0.74 (+2.30%)
Market Cap$2.52B
P/E Ratio—
EPS$—
52W High$35.79
52W Low$17.85
Beta0.95
Data from Finnhub · Updated May 1, 2026